VS-505
- Generic Name
- VS-505
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Shanghai Alebund Pharmaceuticals Limited
- Target Recruit Count
- 158
- Registration Number
- NCT04551300
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath